Skip to main content
Fig. 2 | BMC Medicine

Fig. 2

From: Age and product dependent vaccine effectiveness against SARS-CoV-2 infection and hospitalisation among adults in Norway: a national cohort study, July–November 2021

Fig. 2

Adjusted vaccine effectiveness against infection (A) and hospitalisation (B) for age 18–44 years (blue), 45 to 64 (pink) and 65+ years (green) amongst Norwegian adults using data from 15 July–30 November 2021. Adjusted for age, sex, comorbidities, county of residence, country of birth, and living conditions

Back to article page

BMC Medicine

ISSN: 1741-7015

Contact us